MTAP Deletion and PRMT5: A Metabolic Synthetic Lethality

The Chain of Events

MTAP is an enzyme in the methionine salvage pathway. When MTAP is lost, its substrate methylthioadenosine (MTA) builds up inside the cell. MTA is a partial inhibitor of PRMT5, an arginine methyltransferase, so MTAP-deleted cells run with PRMT5 activity already partially suppressed.

This leaves them with little reserve. A drug that inhibits PRMT5 further pushes these cells below the threshold they need, while cells with intact MTAP and normal MTA levels are relatively spared.

MTA-Cooperative Inhibitors

First-generation PRMT5 inhibitors blocked the enzyme in all cells and were limited by toxicity to normal tissue. Newer compounds are designed to bind PRMT5 only when MTA is also bound, so they act preferentially in the MTA-high environment of MTAP-deleted tumours.

Several such agents are in clinical trials across MTAP-deleted solid tumours, with early evidence of activity. They are investigational, and MTAP status must be confirmed to identify candidates.

Testing Considerations

MTAP loss can be detected as a homozygous deletion on a next-generation sequencing panel or inferred from loss of MTAP protein by immunohistochemistry, which is often used as a surrogate. The two do not always agree.

Because MTAP and CDKN2A are usually co-deleted, an MTAP-loss result generally also implies CDKN2A loss and its cell-cycle consequences.

Why This Example Matters

MTAP deletion is one of the more common targetable events in cancer, present in roughly 10 to 15 percent of tumours overall and enriched in glioblastoma, mesothelioma, and pancreatic and bladder cancers. Unlike most synthetic-lethal ideas it comes with a simple, already-available biomarker — a homozygous deletion visible on standard panels — so patient selection is straightforward.

The MTA-cooperative design is also a template. It shows how a metabolite that accumulates because of a deletion can give a drug tumour selectivity it would not otherwise have, an approach now being applied to other targets. For a report, an MTAP-loss call is worth noting as a trial-eligibility flag even though no MTA-cooperative PRMT5 inhibitor is yet approved.

Key Takeaways

• ·MTAP deletion raises intracellular MTA, which partially inhibits PRMT5 and creates a dependency.
• ·MTA-cooperative PRMT5 inhibitors target MTAP-deleted cells while sparing normal tissue.
• ·MTAP status, by sequencing or immunohistochemistry, identifies candidates and usually implies CDKN2A loss.